Additionally, the blockade of CTLA‐4 can enhance the anti‐HBV response and increase the expansion of HBV‐specific CD8+ T cells capable of producing IFN‐γ, uncovering its potential as a therapeutic target in HCC.204. The gene discussed is IFNG; the disease is hepatocellular carcinoma.